These results suggest that in PC3-DR cells treated with 40 nmol/L DTX, TrkB enhanced DTX resistance in prostate cancer and reversed the effect of LINC01963 silencing and miR-216b-5p overexpression. The gene discussed is NTRK2; the disease is prostate carcinoma.